GB2372446A - Methods for regulating blood glucose and appetite suppression in type 2 diabetics - Google Patents
Methods for regulating blood glucose and appetite suppression in type 2 diabetics Download PDFInfo
- Publication number
- GB2372446A GB2372446A GB0210357A GB0210357A GB2372446A GB 2372446 A GB2372446 A GB 2372446A GB 0210357 A GB0210357 A GB 0210357A GB 0210357 A GB0210357 A GB 0210357A GB 2372446 A GB2372446 A GB 2372446A
- Authority
- GB
- United Kingdom
- Prior art keywords
- type
- methods
- blood glucose
- patient
- food composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 4
- 239000008280 blood Substances 0.000 title abstract description 4
- 210000004369 blood Anatomy 0.000 title abstract description 4
- 239000008103 glucose Substances 0.000 title abstract description 4
- 206010061428 decreased appetite Diseases 0.000 title description 2
- 230000003880 negative regulation of appetite Effects 0.000 title description 2
- 230000001105 regulatory effect Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 abstract description 6
- 229920002261 Corn starch Polymers 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 abstract description 4
- 235000019789 appetite Nutrition 0.000 abstract description 4
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 239000008120 corn starch Substances 0.000 abstract description 4
- 229940099112 cornstarch Drugs 0.000 abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 4
- 208000013016 Hypoglycemia Diseases 0.000 abstract description 2
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pediatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and/or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.
Description
2,UK Patent Application,g,GB,.,2 372 446 PA (43) Date of Printing by UK
Office 28.08.2002 121) Application No 0210357.0 (51) INTCL7 A23L 1/29 1/0522 1/30 1/305 I/ A61P 3/10
(22) Date ofFiling 08.11.2000 (52) UK CL (Edition T) (30) Priority Data A5B B180 B23X B23Y B230 B231 B26Y B31Y B316 (31) 60164043 (32) 08.11.1999 (33) US B827
U1S S1317
(86) International Application Data PCT/US2000/030731 En 08.11.2000 (56) Documents Cited by ISA US 5866555 A US 5843921 A
(87) International Publication Data US 5605893 A (58) Field of Search by ISA
INT CL7 AZ3L
(71) Applicant(s) EPO-INTERNAL,WP1 DATA,PAJ Childrens Hospital Los Angeles Research Institute (Incorporated in USA - Californial 4650 Sunset Boulevard, Mailstop #84, Los Angeles, (74) Agent and/or Address for Service CA 90027, United States of America Harrison Goddard Foote Belgrave Hall, Belgrave Street, LEEDS, LS2 ODD, (72) Inventor(s) United Kingdom Francine R Kaufman (54) Abstract Rtle Methods for regulating blood glucose and appetite suppression in type 2 diabetics (57) Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and/or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. Further disclosed is a method of suppressing appetite in a patient with Type 2 diabetes comprising administering to the subject, in an effective appetite suppressing amount, a food composition that includes a slowly absorbed complex carbohydrate such as uncooked cornstarch. In preferred embodiments, the food composition is in the form of a bar.
Extand Placobo Extend Placabo E,nent Placebo B4r El r 13e r LJ J P value 0.977 co.OOO1 co.OOOl CD D
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16404399P | 1999-11-08 | 1999-11-08 | |
| PCT/US2000/030731 WO2001033976A1 (en) | 1999-11-08 | 2000-11-08 | Methods for regulating blood glucose and appetite suppression in type 2 diabetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0210357D0 GB0210357D0 (en) | 2002-06-12 |
| GB2372446A true GB2372446A (en) | 2002-08-28 |
Family
ID=22592740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0210357A Withdrawn GB2372446A (en) | 1999-11-08 | 2000-11-08 | Methods for regulating blood glucose and appetite suppression in type 2 diabetics |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1476901A (en) |
| GB (1) | GB2372446A (en) |
| WO (1) | WO2001033976A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128955B2 (en) | 1996-05-31 | 2012-03-06 | The Original Creatine Patent Company | Food compositions containing creatine |
| US6248375B1 (en) * | 2000-03-14 | 2001-06-19 | Abbott Laboratories | Diabetic nutritionals and method of using |
| MY135783A (en) | 2001-09-07 | 2008-06-30 | Meiji Dairies Corp | Nutritional composition for controlling blood sugar level |
| EP1410722A1 (en) * | 2002-10-16 | 2004-04-21 | Nutricia N.V. | Weight loss kit and method for losing weight |
| US7220442B2 (en) | 2003-02-20 | 2007-05-22 | Slim-Fast Foods Company, Division Of Conopco, Inc. | Nutrition bar and process of making components |
| JP5448297B2 (en) | 2003-10-16 | 2014-03-19 | テクコム・グループ・リミテッド・ライアビリティ・カンパニー | Reduced digestible carbohydrate food with reduced blood response |
| GB0411985D0 (en) * | 2004-05-28 | 2004-06-30 | Howard Foundation Holdings Ltd | Food compositions containing creatine |
| US20090220649A1 (en) * | 2005-03-14 | 2009-09-03 | Sapporo Holding Limited | Nutritionally Balanced Food or Beverage Product |
| CN112335879A (en) * | 2019-08-07 | 2021-02-09 | 湛江致人生物科技有限公司 | Sugar-controlling prebiotics prepared from exocarpium rubrum and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605893A (en) * | 1994-03-15 | 1997-02-25 | Children's Hospital Of Los Angeles | Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients |
| US5843921A (en) * | 1994-03-15 | 1998-12-01 | Childrens Hospital Of Los Angeles | Therapeutic food composition and method to diminish blood sugar fluctuations |
| US5866555A (en) * | 1997-03-12 | 1999-02-02 | Beth Israel Deaconess Medical Center | Diabetic supplement bar |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0749697A1 (en) * | 1995-06-22 | 1996-12-27 | Hercules Incorporated | Coated food |
| AU2556897A (en) * | 1996-04-12 | 1997-11-07 | Beth Israel Deaconess Medical Center | Diabetic supplement bar |
| US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
-
2000
- 2000-11-08 GB GB0210357A patent/GB2372446A/en not_active Withdrawn
- 2000-11-08 WO PCT/US2000/030731 patent/WO2001033976A1/en active Application Filing
- 2000-11-08 AU AU14769/01A patent/AU1476901A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605893A (en) * | 1994-03-15 | 1997-02-25 | Children's Hospital Of Los Angeles | Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients |
| US5843921A (en) * | 1994-03-15 | 1998-12-01 | Childrens Hospital Of Los Angeles | Therapeutic food composition and method to diminish blood sugar fluctuations |
| US5866555A (en) * | 1997-03-12 | 1999-02-02 | Beth Israel Deaconess Medical Center | Diabetic supplement bar |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001033976A1 (en) | 2001-05-17 |
| AU1476901A (en) | 2001-06-06 |
| GB0210357D0 (en) | 2002-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Broca et al. | 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties | |
| Tilg et al. | Cytokines in alcoholic and nonalcoholic steatohepatitis | |
| WEIR et al. | Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans | |
| Messerli et al. | Antihypertensive therapy and new onset diabetes | |
| GB2372446A (en) | Methods for regulating blood glucose and appetite suppression in type 2 diabetics | |
| Stornello et al. | Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy | |
| Sanyal et al. | A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting | |
| NO20072542L (en) | Pyrimidine derivative condensed with non-aromatic ring | |
| Goldfarb et al. | Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock | |
| Noguchi et al. | A novel preservation solution containing a JNK inhibitory peptide efficiently improves islet yield for porcine islet isolation | |
| SLAKEY et al. | A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function | |
| Noguchi | Regulation of c-Jun NH2-terminal kinase for islet transplantation | |
| Shimamoto et al. | Inhibition of ACh-stimulated exocytosis by NSAIDs in guinea pig antral mucous cells: autocrine regulation of mucin secretion by PGE2 | |
| Horikawa et al. | Synergistic effect of α‐glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment | |
| Callens-El Amrani et al. | Regression of left ventricular hypertrophy by converting enzyme inhibition in 12–15-month-old spontaneously hypertensive rats: effects on coronary resistance and ventricular compliance in normoxia and anoxia | |
| Sakaguchi et al. | Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine | |
| Krakoff | Fasting and ambulatory blood pressure monitoring | |
| Molina et al. | CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS | |
| Coca | High blood pressure and brain oedema in acute stroke: the relevance of ambulatory blood pressure monitoring during the first 24 h after stroke onset | |
| Makaryus et al. | Recurrent reversible dilated cardiomyopathy secondary to viral and streptococcal pneumonia vaccine-associated myocarditis | |
| Almeida et al. | Relapse rates in lepromatous leprosy according to treatment regularity. | |
| Mukundh et al. | Study on Antidiabetic Potential of Sessuvium Portulacastrum Aqueous Extract: An In-Silico and In-Vitro Analysis | |
| Simonsen et al. | Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto–Kakizaki rats | |
| Watson et al. | Intra-epithelial T cells in coeliac disease | |
| Rabon et al. | 666: INCIDENCE AND RISK FACTORS FOR LINEZOLID-ASSOCIATED THROMBOCYTOPENIA IN CRITICALLY ILL PATIENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |